EN | RU
EN | RU

Help Support

Back

JAK inhibitors provide rapid pain relief in psoriatic disease, reveals study

Psoriatic disease Psoriatic disease
Psoriatic disease Psoriatic disease

What's new?

Janus kinase inhibitors provide a safe, effective, and swift treatment for psoriatic disease by targeting crucial inflammatory cytokines.

According to a recent observational, retrospective study published in the journal 'Diagnostics', JAK inhibitors outshined as a fast-acting therapy for psoriatic disorder with good tolerability.

This study by Francesco Bizzarri and colleagues aimed to find the real-world effectiveness, safety, and tolerability of JAK inhibitors (Tofacitinib or Upadacitinib) in Psoriatic Arthritis patients who had failed disease-modifying antirheumatic drugs (DMARD) therapy, addressing gaps in clinical evidence for daily practice.

This study analyzed data from 32 Psoriatic Arthritis patients treated with Tofacitinib or Upadacitinib after DMARD failure within the past two years. Predominantly 75% of patients initiated Tofacitinib. Most of these patients displayed moderate arthritis and mild psoriasis activity based on disease activity indices.

 Both Tofacitinib and Upadacitinib displayed remarkable effectiveness, swiftly improving joint and skin activity indices, reducing C-reactive protein, and decreasing objective disease markers like painful and inflamed joints. A few mild adverse events necessitated treatment discontinuation, with no serious incidents were registered.

Source:

MDPI - Diagnostics

Article:

JAKinhibs in Psoriatic Disease: Analysis of the Efficacy/Safety Profile in Daily Clinical Practice

Authors:

Francesco Bizzarri et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: